Search

Displaying results 8071 - 8080 of 10000 in total
  1. Drug

    4-Methoxyamphetamine

    go.drugbank.com/drugs/DB01472
    ExperimentalIllicit

  2. Drug

    Tersolisib

    go.drugbank.com/drugs/DB21752
    Investigational

    STX-478 is under investigation in clinical trail NCT05768139 (First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  3. Drug

    Hycanthone

    go.drugbank.com/drugs/DB14061
    Experimental

    Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE. Hycanthone was approved by the FDA in 1975 but is no longer used.

  4. Drug

    siG12D LODER

    go.drugbank.com/drugs/DB16329
    Investigational

    siG12D LODER is under investigation in clinical trial NCT01676259 (A Phase 2 Study of Sig12d LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer).

  5. Drug

    Vorbipiprant

    go.drugbank.com/drugs/DB16111
    Investigational

    CR6086 is under investigation in clinical trial NCT03163966 (A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in Dmard-naïve Patients With Early Rheumatoid Arthritis).

  6. Drug

    Zirconium panitumumab Zr-89

    go.drugbank.com/drugs/DB19228
    Investigational

    Zirconium panitumumab Zr-89 is under investigation in clinical trial NCT05423197 (Study Evaluating Zr-panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous

  7. Drug

    EGT-301

    go.drugbank.com/drugs/DB17649
    Experimental

    It consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase (I2S) transgene designed to restore I2S functional deficiency in patients with Hunter syndrome … EGT-301 is a gene therapy being investigated for Hunter Syndrome.

  8. Drug

    CX-2009

    go.drugbank.com/drugs/DB16090
    Investigational

    CX-2009 is under investigation in clinical trial NCT03149549 (PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors).

  9. Drug

    AM103

    go.drugbank.com/drugs/DB05225
    Experimental

    It is being developed by Amira. … AM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation

  10. Drug

    Uliledlimab

    go.drugbank.com/drugs/DB16675
    Investigational

    Uliledlimab is under investigation in clinical trial NCT04322006 (A Phase I/II Study of TJ004309 for Advanced Solid Tumor).